469 related articles for article (PubMed ID: 34022266)
1. Phosphorylated α-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis.
Rong Z; Shen F; Wang Y; Sun L; Wu J; Zhang H; Yuan Y; Jiang W; Li X; Ji P; Zhang K
Neurosci Lett; 2021 Jun; 756():135964. PubMed ID: 34022266
[TBL] [Abstract][Full Text] [Related]
2. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
[TBL] [Abstract][Full Text] [Related]
3. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
Vivacqua G; Suppa A; Mancinelli R; Belvisi D; Fabbrini A; Costanzo M; Formica A; Onori P; Fabbrini G; Berardelli A
Parkinsonism Relat Disord; 2019 Jun; 63():143-148. PubMed ID: 30796010
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated α-synuclein deposits in sural nerve deriving from Schwann cells: A biomarker for Parkinson's disease.
Zhang H; Zhu L; Sun L; Zhi Y; Ding J; Yuan YS; Shen FF; Li X; Ji P; Wang Z; Niu Q; Zhang KZ
Parkinsonism Relat Disord; 2019 Mar; 60():57-63. PubMed ID: 30297212
[TBL] [Abstract][Full Text] [Related]
5. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
[TBL] [Abstract][Full Text] [Related]
6. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.
Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M
Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435
[TBL] [Abstract][Full Text] [Related]
7. Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
Huang SY; Chen SF; Cui M; Zhao M; Shen XN; Guo Y; Zhang YR; Zhang W; Wang HF; Huang YY; Cheng W; Zuo CT; Dong Q; Yu JT
Mov Disord; 2023 Apr; 38(4):676-682. PubMed ID: 36781585
[TBL] [Abstract][Full Text] [Related]
8. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
[TBL] [Abstract][Full Text] [Related]
9. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
[TBL] [Abstract][Full Text] [Related]
10. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.
Song YJ; Halliday GM; Holton JL; Lashley T; O'Sullivan SS; McCann H; Lees AJ; Ozawa T; Williams DR; Lockhart PJ; Revesz TR
J Neuropathol Exp Neurol; 2009 Oct; 68(10):1073-83. PubMed ID: 19918119
[TBL] [Abstract][Full Text] [Related]
11. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging.
Tsukamoto K; Matsusue E; Kanasaki Y; Kakite S; Fujii S; Kaminou T; Ogawa T
Neuroradiology; 2012 Sep; 54(9):947-55. PubMed ID: 22274571
[TBL] [Abstract][Full Text] [Related]
12. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ
Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022
[TBL] [Abstract][Full Text] [Related]
13. Coexistence of PSP and MSA: a case report and review of the literature.
Uchikado H; DelleDonne A; Uitti R; Dickson DW
Acta Neuropathol; 2006 Feb; 111(2):186-92. PubMed ID: 16456665
[TBL] [Abstract][Full Text] [Related]
14. Presence of Skin α-Synuclein Deposits Discriminates Parkinson's Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome.
Giannoccaro MP; Avoni P; Rizzo G; Incensi A; Infante R; Donadio V; Liguori R
J Parkinsons Dis; 2022; 12(2):585-591. PubMed ID: 34864689
[TBL] [Abstract][Full Text] [Related]
15. A Card-type Odor Identification Test for Japanese Patients with Parkinson's Disease and Related Disorders.
Watanabe Y; Suzuki K; Miyamoto T; Miyamoto M; Numao A; Fujita H; Uchiyama T; Kadowaki T; Matsubara T; Hirata K
Intern Med; 2017 Nov; 56(21):2871-2878. PubMed ID: 28943542
[TBL] [Abstract][Full Text] [Related]
16. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
[TBL] [Abstract][Full Text] [Related]
17. The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy.
Suzuki M; Hashimoto M; Yoshioka M; Murakami M; Kawasaki K; Urashima M
BMC Neurol; 2011 Dec; 11():157. PubMed ID: 22192419
[TBL] [Abstract][Full Text] [Related]
18. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
Paviour DC; Thornton JS; Lees AJ; Jäger HR
Mov Disord; 2007 Jan; 22(1):68-74. PubMed ID: 17089396
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
